10 Undervalued Wide Moat Stocks to Buy Now

5. Amgen Inc. (NASDAQ:AMGN)

Forward Price-to-Earnings: 15.02x

Number of Hedge Fund Holders: 62

Amgen Inc. (NASDAQ:AMGN) is one of the best undervalued wide moat stocks.

On January 13, 2026, an announcement came regarding the Ro and Amgen Inc. (NASDAQ:AMGN) collaboration. Ro, a U.S. telehealth firm, alongside Amgen, aims to investigate barriers patients face in accessing obesity treatments, including GLP-1 drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Zepbound.

Leveraging data from Ro’s direct-to-consumer platform, both companies aim to assess insurance coverage and prior authorization requirements, identify caps, and improve patient access. The companies noted that GLP-1 therapies can be life-changing, with the broad impact depending on how access is scaled. Meanwhile, Amgen Inc. (NASDAQ:AMGN) aims to capitalize on the observational research, expecting the research to help with therapy development and bring innovations in care delivery. However, the financial terms were not disclosed.

A week earlier, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics for up to $840 million. Dark Blue is a UK-based biotech company that is advancing first-in-class small molecule protein degraders targeting MLLT1/3 proteins in acute myeloid leukemia (AML). Showing anti-cancer activity and differentiation from existing therapies, the preclinical data support potential single-agent and combination treatment strategies. As it prepares to integrate Dark Blue into its research organization, the company aims to bolster early oncology discovery and reinforce its commitment to novel therapeutic mechanisms.

Amgen Inc. (NASDAQ:AMGN), a biotechnology company, develops, manufactures, and markets human therapeutics. The company was founded in 1980 and is headquartered in Thousand Oaks, CA.